Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat

Intestinal lipid absorption is associated with marked increases in the synthesis and secretion of apolipoprotein A-IV (apoA-IV) by the small intestine. Whether the increased intestinal apoA-IV synthesis and secretion results from increased fat uptake, increased cellular triglyceride (TG) content, or...

Full description

Bibliographic Details
Main Authors: H Hayashi, DF Nutting, K Fujimoto, JA Cardelli, D Black, P Tso
Format: Article
Language:English
Published: Elsevier 1990-09-01
Series:Journal of Lipid Research
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520423454
id doaj-24efbf2fb1db44dd8eb9b14aee52c199
record_format Article
spelling doaj-24efbf2fb1db44dd8eb9b14aee52c1992021-04-25T04:22:16ZengElsevierJournal of Lipid Research0022-22751990-09-0131916131625Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the ratH Hayashi0DF Nutting1K Fujimoto2JA Cardelli3D Black4P Tso5Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.Intestinal lipid absorption is associated with marked increases in the synthesis and secretion of apolipoprotein A-IV (apoA-IV) by the small intestine. Whether the increased intestinal apoA-IV synthesis and secretion results from increased fat uptake, increased cellular triglyceride (TG) content, or increased secretion of TG-rich lipoproteins by the enterocytes is unknown. Previous work from this laboratory has shown that a hydrophobic surfactant, Pluronic L-81 (L-81), is a potent inhibitor of intestinal formation of chylomicrons (CM), without reducing fat uptake or re-synthesis to TG. Furthermore, this inhibition can be reversed quickly by the cessation of L-81 infusion. Thus L-81 offers a unique opportunity to study the relationship between lymphatic TG, apoA-I and A-IV secretion. In this study, we studied the lymphatic transport of TG, apoA-I, and apoA-IV during both the inhibitory phase (L-81 infused together with lipid) and the subsequent unblocking phase (saline infusion). Two groups of lymph fistula rats were used, the control and the experimental rats. In the experimental rats, a phosphate-buffered taurocholate-stabilized emulsion containing 40 mumol [3H]triolein, 7.8 mumol of phosphatidylcholine, and 1 mg L-81 per 3 ml was infused at 3 ml/h for 8 h. This was then replaced by glucose-saline infusion for an additional 12 h. The control rats received the same lipid emulsion as the experimental rats, but without L-81 added, for 8 h. Lymph lipid was determined both by radioactivity and by glyceride-glycerol determination, and the apoA-I and apoA-IV concentrations were determined by rocket electroimmunophoresis assay. L-81 inhibited the rise in lymphatic lipid and apoA-IV output in the experimental rats after the beginning of lipid + L-81 infusion. Upon cessation of L-81 infusion, the mucosal lipid accumulated as a result of L-81 treatment was rapidly cleared into lymph as CM. This was associated with a marked increase in apoA-IV output; the maximal output was about 3 times that of the fasting level. There was a time lag of 4-5 h between the peak lymph lipid output and the peak lymph apoA-IV output during the unblocking phase in the experimental rats. There was also a comparable time lag between the maximal lipid and apoA-IV outputs in the control animals. Incorporation studies using [3H]leucine showed that apoA-IV synthesis was not stimulated during lipid + L-81 infusion, perhaps explaining the lack of increase in lymphatic A-IV secretion.(ABSTRACT TRUNCATED AT 400 WORDS)http://www.sciencedirect.com/science/article/pii/S0022227520423454
collection DOAJ
language English
format Article
sources DOAJ
author H Hayashi
DF Nutting
K Fujimoto
JA Cardelli
D Black
P Tso
spellingShingle H Hayashi
DF Nutting
K Fujimoto
JA Cardelli
D Black
P Tso
Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
Journal of Lipid Research
author_facet H Hayashi
DF Nutting
K Fujimoto
JA Cardelli
D Black
P Tso
author_sort H Hayashi
title Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
title_short Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
title_full Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
title_fullStr Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
title_full_unstemmed Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat
title_sort transport of lipid and apolipoproteins a-i and a-iv in intestinal lymph of the rat
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 1990-09-01
description Intestinal lipid absorption is associated with marked increases in the synthesis and secretion of apolipoprotein A-IV (apoA-IV) by the small intestine. Whether the increased intestinal apoA-IV synthesis and secretion results from increased fat uptake, increased cellular triglyceride (TG) content, or increased secretion of TG-rich lipoproteins by the enterocytes is unknown. Previous work from this laboratory has shown that a hydrophobic surfactant, Pluronic L-81 (L-81), is a potent inhibitor of intestinal formation of chylomicrons (CM), without reducing fat uptake or re-synthesis to TG. Furthermore, this inhibition can be reversed quickly by the cessation of L-81 infusion. Thus L-81 offers a unique opportunity to study the relationship between lymphatic TG, apoA-I and A-IV secretion. In this study, we studied the lymphatic transport of TG, apoA-I, and apoA-IV during both the inhibitory phase (L-81 infused together with lipid) and the subsequent unblocking phase (saline infusion). Two groups of lymph fistula rats were used, the control and the experimental rats. In the experimental rats, a phosphate-buffered taurocholate-stabilized emulsion containing 40 mumol [3H]triolein, 7.8 mumol of phosphatidylcholine, and 1 mg L-81 per 3 ml was infused at 3 ml/h for 8 h. This was then replaced by glucose-saline infusion for an additional 12 h. The control rats received the same lipid emulsion as the experimental rats, but without L-81 added, for 8 h. Lymph lipid was determined both by radioactivity and by glyceride-glycerol determination, and the apoA-I and apoA-IV concentrations were determined by rocket electroimmunophoresis assay. L-81 inhibited the rise in lymphatic lipid and apoA-IV output in the experimental rats after the beginning of lipid + L-81 infusion. Upon cessation of L-81 infusion, the mucosal lipid accumulated as a result of L-81 treatment was rapidly cleared into lymph as CM. This was associated with a marked increase in apoA-IV output; the maximal output was about 3 times that of the fasting level. There was a time lag of 4-5 h between the peak lymph lipid output and the peak lymph apoA-IV output during the unblocking phase in the experimental rats. There was also a comparable time lag between the maximal lipid and apoA-IV outputs in the control animals. Incorporation studies using [3H]leucine showed that apoA-IV synthesis was not stimulated during lipid + L-81 infusion, perhaps explaining the lack of increase in lymphatic A-IV secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
url http://www.sciencedirect.com/science/article/pii/S0022227520423454
work_keys_str_mv AT hhayashi transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
AT dfnutting transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
AT kfujimoto transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
AT jacardelli transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
AT dblack transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
AT ptso transportoflipidandapolipoproteinsaiandaivinintestinallymphoftherat
_version_ 1721510220476186624